BMS’ oral plaque psoriasis drug Sotyktu gets reimbursement starting April < Pharma < Article

Starting this month, Sotyktu (deucravacitinib), an oral treatment for moderate-to-severe plaque psoriasis in adults, receives health insurance benefits in Korea for treating adult patients with chr...

Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to sev - MilliporeSigma

Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry. by M Inzinger, B Heschl, W Weger, A...

HUMIRA® (adalimumab) for Plaque Psoriasis (PS)

HUMIRA® (adalimumab) is a biologic for adults with moderate to severe chronic plaque psoriasis (PS). See Important Safety Info, including the BOXED WARNING.

Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to sev - MilliporeSigma

Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry. by M Inzinger, B Heschl, W Weger, A...

Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to sev - ResearchGate

Request PDF | Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: Retrospective data analysis of a patient registry | Few studies have dire...

Moderate and severe plaque psoriasis: cost-of-illness study in Italy

Psoriasis is a chronic inflammatory, immune-mediated skin disorder that affects 1.5-1.8 million people in Italy. The most common form of the disease is chronic plaque psoriasis, affecting about 90%...

Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An E

for moderate-to-severe plaque psoriasis. Research questions: The specific research questions... Clinical need: TARGET POPULATION AND CONDITION Psoriasis is a common chronic, systemic...

Certolizumab pegol for the treatment of patients with moderate-to-severe chronic

Methods: In each trial, patients ≥18 years with moderate-to-severe chronic plaque psoriasis for ≥6 months were randomized to receive certolizumab 400 mg, certolizumab 200 mg or placebo...

Frontiers | Understanding efficacy-safety balance of biologics in moderate-to-se

Background: Psoriasis is a chronic immune-mediated inflammatory skin disease affecting both... of moderate-to-severe plaque psoriasis in adults and most compounds have recently been...

Moderate to Severe Plaque Psoriasis Treatment| ENBREL® (etanercept)

Read more about ENBREL® (etanercept) for patients, 4 years and older, with moderate to severe plaque psoriasis. See Full Prescribing & Safety Info.